US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neumora Therapeutics, Inc.

0.7798

+0.01281.67%

Pre-market: 0.7510-0.0288-3.69%08:01 EDT

Volume:804.65K

Turnover:613.83K

Market Cap:126.13M

PE:-0.51

High:0.7798

Open:0.7630

Low:0.7315

Close:0.7670

Loading ...

Overview Company News Filings

Sector Update: Health Care Stocks Ease Thursday Afternoon

MT Newswires Live

Neumora Nosedives 80% At Pre-Market on Failed Depression Drug Trial

Buy Rating Maintained for Neumora Therapeutics Due to Promising MDD Trial Results and Strong Financial Position

H.C. Wainwright still sees opportunity for Neumora despite trial miss

Top Stock Movers Now: Uber, Unity Software, Tesla, and More

Neumora Therapeutics Inc : RBC Cuts to Sector Perform From Outperform

THOMSON REUTERS

RBC Downgrades Neumora Therapeutics to Sector Perform From Outperform, Price Target is $4

MT Newswires Live

RBC downgrades Neumora Therapeutics to Sector Perform after trial failure

Neumora Therapeutics downgraded to Sector Perform from Outperform at RBC Capital

Neumora Stock Dives After Study Failure -- WSJ

Neumora Therapeutics shares plunge as depression treatment misses trial targets

Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals

BUZZ-Neumora hits record low as depression drug fails in late-stage study

Neumora Therapeutics' stock craters after trial of major depressive disorder fails to meet main goals

Stock in Biotech Neumora Plunges 80% as Depression Drug Fails -- Barrons.com

Neumora Therapeutics Inc trading resumes

Optimistic Buy Rating for Neumora Therapeutics Despite Recent Clinical Setback

Neumora Therapeutics Inc trading halted, volatility trading pause

Neumora Therapeutics Price Target Maintained With a $23.00/Share by Needham

Neumora Shares Down 82.5% After Co's Depression Drug Fails to Meet Main Goal in a Late-Stage Trial

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NMRA/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NMRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NMRA\",,,,,undefined,":{"symbol":"NMRA","market":"US","secType":"STK","nameCN":"Neumora Therapeutics, Inc.","latestPrice":0.7798,"timestamp":1746043200000,"preClose":0.767,"halted":0,"volume":804653,"hourTrading":{"tag":"盘前","latestPrice":0.751,"preClose":0.7798,"latestTime":"08:01 EDT","volume":874,"amount":681.51639296,"timestamp":1746100913348},"delay":0,"floatShares":53359830,"shares":161747922,"eps":-1.529624,"marketStatus":"Pre-Mkt","change":0.0128,"latestTime":"05-01 08:21:44 EDT","open":0.763,"high":0.7798,"low":0.7315,"amount":613825.8396462,"amplitude":0.062973,"askPrice":0.85,"askSize":200,"bidPrice":0.7677,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-1.529624,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746106200000},"marketStatusCode":1,"adr":0,"listingDate":1694750400000,"exchange":"NASDAQ","adjPreClose":0.7798,"preHourTrading":{"tag":"盘前","latestPrice":0.751,"preClose":0.7798,"latestTime":"08:01 EDT","volume":874,"amount":681.51639296,"timestamp":1746100913348},"postHourTrading":{"tag":"盘后","latestPrice":0.77,"preClose":0.7798,"latestTime":"19:21 EDT","volume":2615,"amount":2034.6734,"timestamp":1746055289688},"volumeRatio":0.8030364874143188,"impliedVol":0.8389,"impliedVolPercentile":0.3494},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NMRA\",,,,,undefined,":{"symbol":"NMRA","floatShares":53359830,"roa":"-40.50%","roe":"-64.48%","lyrEps":-1.529624,"volumeRatio":0.8030364874143188,"shares":161747922,"dividePrice":0,"high":0.7798,"amplitude":0.062973,"preClose":0.767,"low":0.7315,"week52Low":0.6211,"pbRate":"0.44","week52High":17.1874,"institutionHeld":0,"latestPrice":0.7798,"committee":-0.980198,"eps":-1.529624,"divideRate":0,"volume":804653,"delay":0,"ttmEps":-1.529624,"open":0.763,"prevYearClose":10.6,"prevWeekClose":0.7575,"prevMonthClose":0.7798,"prevQuarterClose":1,"fiveDayClose":0.7109,"twentyDayClose":0.9133,"sixtyDayClose":1.86,"earningDate":1746979200000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NMRA\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2500908010","title":"Sector Update: Health Care Stocks Ease Thursday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2500908010","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500908010?lang=en_us&edition=fundamental","pubTime":"2025-01-03 02:53","pubTimestamp":1735844031,"startTime":"0","endTime":"0","summary":"Health care stocks fell Thursday afternoon, with the NYSE Health Care Index easing 0.1% and the Health Care Select Sector SPDR Fund  decreasing 0.3%.The iShares Biotechnology ETF  rose 0.2%.In corporate news, NRX Pharmaceuticals  shares surged 38%. The Hope Therapeutics unit plans to acquire the Kadima Neuropsychiatry Institute.Avalo Therapeutics  shares jumped 14. Jennifer Riley was appointed to the newly created role of chief strategy officer.Neumora Therapeutics  shares plunged 82% after a phase 3 trial of navacaprant to treat major depressive disorder failed to meet the primary endpoint.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NRXP","XLV","BK4581","IBB","AVTX","BK4139","BK4585","NMRA","BK4007","BK4588"],"gpt_icon":0},{"id":"2500908298","title":"Neumora Nosedives 80% At Pre-Market on Failed Depression Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2500908298","media":"Insider Monkey","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500908298?lang=en_us&edition=fundamental","pubTime":"2025-01-03 02:28","pubTimestamp":1735842536,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Inc.  nosedived by more than 80 percent during pre-market trading following disappointing results from the Phase 3 trial of navacaprant, a drug being developed to treat major depressive disorders.A man leaning on a wooden table. Photo by Andrew Neel on Pexels. According to the company, the study failed to show a statistically significant improvement in depressive symptoms compared to placebo as measured by the Montgomery-sberg Depression Rating Scale . The asset was tested on 383 adult patients.Neumora  said it plans to further analyze such findings.Neumora Therapeutics has a therapeutic pipeline of seven clinical and preclinical neuroscience programs targeting a range of brain diseases. It is on a mission to redefine neuroscience drug development by advancing novel therapies for improved treatment outcomes.While we acknowledge the potential of NMRA, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neumora-nosedives-80-pre-market-182856393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVIW.SI",".IXIC","TQQQ","USJW.SI","PSQ","BK4017","QLD","MNQmain","BK4007","TSYW.SI","NQmain","SQQQ","NMRA","QID","USAW.SI","KOR"],"gpt_icon":1},{"id":"2500977108","title":"Buy Rating Maintained for Neumora Therapeutics Due to Promising MDD Trial Results and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2500977108","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500977108?lang=en_us&edition=fundamental","pubTime":"2025-01-03 01:55","pubTimestamp":1735840518,"startTime":"0","endTime":"0","summary":"Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Neumora Therapeutics, Inc. (NMRA – Research Report) and keeping the price targ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-maintained-for-neumora-therapeutics-due-to-promising-mdd-trial-results-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-maintained-for-neumora-therapeutics-due-to-promising-mdd-trial-results-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NMRA","LENZ","ABVC"],"gpt_icon":0},{"id":"2500771759","title":"H.C. Wainwright still sees opportunity for Neumora despite trial miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2500771759","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500771759?lang=en_us&edition=fundamental","pubTime":"2025-01-03 01:50","pubTimestamp":1735840218,"startTime":"0","endTime":"0","summary":"H.C. Wainwright says that while Neumora Therapeutics (NMRA)’ KOASTAL-1 result “was a surprise and disappointment,” the better results for female pa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-still-sees-opportunity-for-neumora-despite-trial-miss?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-still-sees-opportunity-for-neumora-despite-trial-miss?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2500972401","title":"Top Stock Movers Now: Uber, Unity Software, Tesla, and More","url":"https://stock-news.laohu8.com/highlight/detail?id=2500972401","media":"Investopedia","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500972401?lang=en_us&edition=fundamental","pubTime":"2025-01-03 01:00","pubTimestamp":1735837247,"startTime":"0","endTime":"0","summary":"U.S. equities edged higher on the first trading day of the new year as optimism about corporate growth in the future was dampened somewhat by concerns about the tech sector.Uber Technologies and Norwegian Cruise Line Holdings were added to Goldman Sachs' U.S. Conviction List.Apple cut prices of its iPhone in China as competition in the cellphone market there heats up.U.S. equities began 2025 trading by edging higher at midday, as positive analysts' comments were offset somewhat by technology concerns. The Dow Jones Industrial Average gave up big early gains to trade up 0.2%, while the S&P 500 and Nasdaq were 0.4% and 0.5% higher, respectively.Shares of Uber Technologies  and Norwegian Cruise Line Holdings  advanced when Goldman Sachs added both to its U.S. Conviction List, arguing both have promising growth potential ahead.Shares of Unity Software  took off after \"Roaring Kitty\" posted a clip on X of the late singer Rick James, who had a song called \"Unity,” which some saw as a sign th","market":"hk","thumbnail":"https://www.investopedia.com/thmb/5egTqhVwjmpZlNPCag8Dvm7y0s0=/6960x4640/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2191454932-bbedf00ec648436ca373f6192d30e2bf.jpg","type":0,"news_type":0,"thumbnails":["https://www.investopedia.com/thmb/5egTqhVwjmpZlNPCag8Dvm7y0s0=/6960x4640/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2191454932-bbedf00ec648436ca373f6192d30e2bf.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investopedia.com/top-stock-movers-now-uber-unity-software-tesla-and-more-8768209","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investopedia_highlight","symbols":["IE00BJJMRY28.SGD","LU2023250843.SGD","LU1301847155.USD","LU1674673428.USD","LU0354030511.USD","BK4023","IE00BKDWB100.SGD","LU0157215616.USD","LU2264538146.SGD","LU0724618789.USD","LU1791710582.SGD","NEM.AU","LU0289961442.SGD","LU0109391861.USD","BK4505","MACW.SI","NCLH","BK4127","LU1496350502.SGD","UNTY","LU0330918003.SGD","LU0055631609.USD","UBER","NEM","IE00BLSP4452.SGD","IE00B4YYXB79.USD","LU0820562030.AUD","LU2552382058.USD","TSLA","LU1206713676.USD","LU1934455194.USD","TSYW.SI","IE000YTNTUN2.SGD","AAPL","U","LU2106854487.HKD","NMRA","LU0689472784.USD","LU0820561909.HKD","LU2242649171.HKD","BK4532","LU0553294199.USD","LU1267930730.SGD","LU2097344431.USD","LU2357305700.SGD","LU0496367417.USD","LU0345769128.USD","LU0300736062.USD","TSLL"],"gpt_icon":1},{"id":"2500463976","title":"Neumora Therapeutics Inc : RBC Cuts to Sector Perform From Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2500463976","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500463976?lang=en_us&edition=fundamental","pubTime":"2025-01-03 00:16","pubTimestamp":1735834583,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250102:nFWN3NY0AY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2500167976","title":"RBC Downgrades Neumora Therapeutics to Sector Perform From Outperform, Price Target is $4","url":"https://stock-news.laohu8.com/highlight/detail?id=2500167976","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500167976?lang=en_us&edition=fundamental","pubTime":"2025-01-03 00:14","pubTimestamp":1735834465,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics (NMRA) has an average rating of buy and mean price target of $23.49, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NMRA","LENZ"],"gpt_icon":0},{"id":"2500761919","title":"RBC downgrades Neumora Therapeutics to Sector Perform after trial failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2500761919","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500761919?lang=en_us&edition=fundamental","pubTime":"2025-01-03 00:10","pubTimestamp":1735834212,"startTime":"0","endTime":"0","summary":"RBC Capital downgraded Neumora Therapeutics (NMRA) to Sector Perform from Outperform with a price target of $4, down from $29, following lead drug ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rbc-downgrades-neumora-therapeutics-to-sector-perform-after-trial-failure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rbc-downgrades-neumora-therapeutics-to-sector-perform-after-trial-failure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","NMRA"],"gpt_icon":0},{"id":"2500976116","title":"Neumora Therapeutics downgraded to Sector Perform from Outperform at RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2500976116","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500976116?lang=en_us&edition=fundamental","pubTime":"2025-01-03 00:05","pubTimestamp":1735833924,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams downgraded Neumora Therapeutics (NMRA) to Sector Perform from Outperform with a price target of $4, down from $2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-downgraded-to-sector-perform-from-outperform-at-rbc-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-downgraded-to-sector-perform-from-outperform-at-rbc-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","NMRA"],"gpt_icon":0},{"id":"2500032975","title":"Neumora Stock Dives After Study Failure -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2500032975","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500032975?lang=en_us&edition=fundamental","pubTime":"2025-01-03 00:03","pubTimestamp":1735833780,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics shares plunged more than 80% on Thursday after its lead drug candidate failed to help patients with depression in a study.The drug, called navacaprant, was no better than a placebo in the trial, the first of three Phase 3 studies the company is running in hopes of gaining U.S. approval.\"Today's readout represents a worst-case scenario for the program,\" said RBC Capital Markets analyst Brian Abrahams in a note to clients.Neumora shares fell 81% to $2.00 in early trading.The company said it has cash of $342 million that will allow it to survive into at least mid-2026.This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL .","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2500973021","title":"Neumora Therapeutics shares plunge as depression treatment misses trial targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2500973021","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500973021?lang=en_us&edition=fundamental","pubTime":"2025-01-02 23:48","pubTimestamp":1735832880,"startTime":"0","endTime":"0","summary":"This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","NMRA"],"gpt_icon":0},{"id":"2500455976","title":"Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals","url":"https://stock-news.laohu8.com/highlight/detail?id=2500455976","media":"Investopedia","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500455976?lang=en_us&edition=fundamental","pubTime":"2025-01-02 23:47","pubTimestamp":1735832826,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics reported its experimental depression drug didn't meet expectations, and shares plunged.The biopharmaceutical firm's navacaprant treatment failed to reach both primary and secondary endpoints.The company said it would continue to investigate the results and provide more information at a conference later this month.Neumora Therapeutics  shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a late-stage study of its experimental treatment for depression did not meet its goals.The company reported that in the first of three Phase 3 trials, the drug navacaprant \"did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-sberg Depression Rating Scale  total score at Week 6 or the key secondary endpoint of a change from baseline in the Snaith-Hamilton Pleasure Scale  scale.\". Rob Lenz, the head of research and development at Neumora, said the company was \"disappointe","market":"sg","thumbnail":"https://www.investopedia.com/thmb/rj1RgFv5qLpw76mwTohdhJs0Cng=/4927x3284/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2167102223-b3724671abba400daaa8415a07f41ac2.jpg","type":0,"news_type":0,"thumbnails":["https://www.investopedia.com/thmb/rj1RgFv5qLpw76mwTohdhJs0Cng=/4927x3284/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2167102223-b3724671abba400daaa8415a07f41ac2.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investopedia.com/neumora-therapeutics-stock-tanks-as-its-depression-drug-misses-goals-8768109","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investopedia_highlight","symbols":["BK4007","BK4139","LENZ","NMRA"],"gpt_icon":0},{"id":"2500973102","title":"BUZZ-Neumora hits record low as depression drug fails in late-stage study","url":"https://stock-news.laohu8.com/highlight/detail?id=2500973102","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500973102?lang=en_us&edition=fundamental","pubTime":"2025-01-02 23:42","pubTimestamp":1735832538,"startTime":"0","endTime":"0","summary":"BUZZ-Neumora hits record low as depression drug fails in late-stage studyUpdates** Drug developer Neumora Therapeutics' NMRA.O shares fall 80% to $2.08, hitting lowest level since its Nasdaq debut. ** Stock on track for biggest one-day percentage fall since debut if losses hold. ** NMRA says its experimental depression drug, navacaprant, did not meet the main goal in a late-stage trial** The drug did not reduce symptoms of depression as measured on a disease severity scale that tracks sadness, reduced sleep and pessimistic thoughts** NMRA says the drug also did not improve anhedonia, a patients' inability to feel pleasure — a key secondary goal in the study** Brokerage RBC Capital Markets says results \"represent a worst-case scenario for the program\". ** Brokerage Needham says data \"reduces the likelihood\" of the drug succeeding in two other late-stage studies. ** NMRA plans to discuss updates on development of the drug at an industry conference later this month. ** Co says its cash ba","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250102:nL4N3NY0LY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2500978408","title":"Neumora Therapeutics' stock craters after trial of major depressive disorder fails to meet main goals","url":"https://stock-news.laohu8.com/highlight/detail?id=2500978408","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500978408?lang=en_us&edition=fundamental","pubTime":"2025-01-02 23:27","pubTimestamp":1735831620,"startTime":"0","endTime":"0","summary":"News is a setback for the clinical-stage biotech and a drug that proved successful in earlier trials. Neumora Therapeutics Inc.'s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals.The Watertown, Mass.-based company  said the Phase 3 trial of navacaprant failed to demonstrate statistically significant improvement on the primary endpoint of reduction in depressive symptom compared to placebo at week 6.Navacaprant is the company's main product candidate, and was measured using the Montgomery-sberg Depression Rating Scale, or MADRS, a 10-question diagnostic questionnaire used by mental-health professionals to measure the severity of depressive symptoms.The treatment did show an efficacy signal in women, however and the company will further analyze the data, he said.\"There is a lot to investigate from this study, in particular the contrast in drug and placebo responses in depressed ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ABVC","LENZ","NMRA"],"gpt_icon":0},{"id":"2500920883","title":"Stock in Biotech Neumora Plunges 80% as Depression Drug Fails -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2500920883","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500920883?lang=en_us&edition=fundamental","pubTime":"2025-01-02 22:59","pubTimestamp":1735829940,"startTime":"0","endTime":"0","summary":"Shares of the biotech Neumora Therapeutics began the first trading day of 2025 with a loss of more than 80% after the company said that its experimental depression drug failed in a key trial.Patients who received the drug, called navacaprant, showed no more improvement in depressive symptoms than people who received a placebo. The Phase 3 trial was the first of three that were intended to pave the way for the drug's approval as a treatment for major depressive disorder.But there is still hope for Neumora, which has no approved drug in its portfolio. Navacaprant could perform better in the two continuing Phase 3 trials. And while navacaprant is Neumora's lead pipeline asset, the company has a handful of other drugs in earlier phases of testing.Neumora said Thursday that it has enough cash on hand to operate through the middle of 2026.For male participants, however, the drug appeared to work worse than the placebo. Male participants saw a 10.6-point reduction on navacaprant, and a 13.8-p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2500927441","title":"Neumora Therapeutics Inc trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2500927441","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500927441?lang=en_us&edition=fundamental","pubTime":"2025-01-02 22:41","pubTimestamp":1735828866,"startTime":"0","endTime":"0","summary":"09:39 EST Neumora Therapeutics (NMRA) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking fin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-inc-trading-resumes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-inc-trading-resumes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4139","NMRA"],"gpt_icon":0},{"id":"2500922988","title":"Optimistic Buy Rating for Neumora Therapeutics Despite Recent Clinical Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2500922988","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500922988?lang=en_us&edition=fundamental","pubTime":"2025-01-02 22:35","pubTimestamp":1735828516,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NMRA stock, giving a Buy rating today. Paul Matteis has given his Buy r...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/optimistic-buy-rating-for-neumora-therapeutics-despite-recent-clinical-setback?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/optimistic-buy-rating-for-neumora-therapeutics-despite-recent-clinical-setback?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","NMRA"],"gpt_icon":0},{"id":"2500092250","title":"Neumora Therapeutics Inc trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2500092250","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500092250?lang=en_us&edition=fundamental","pubTime":"2025-01-02 22:35","pubTimestamp":1735828510,"startTime":"0","endTime":"0","summary":"09:34 EST Neumora Therapeutics (NMRA) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, m...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-inc-trading-halted-volatility-trading-pause?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-inc-trading-halted-volatility-trading-pause?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4139","NMRA"],"gpt_icon":0},{"id":"2500922855","title":"Neumora Therapeutics Price Target Maintained With a $23.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2500922855","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500922855?lang=en_us&edition=fundamental","pubTime":"2025-01-02 22:33","pubTimestamp":1735828380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NMRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 02, 2025 09:33 ET (14:33 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","NMRA"],"gpt_icon":0},{"id":"2500041924","title":"Neumora Shares Down 82.5% After Co's Depression Drug Fails to Meet Main Goal in a Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2500041924","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500041924?lang=en_us&edition=fundamental","pubTime":"2025-01-02 22:31","pubTimestamp":1735828313,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250102:nL4N3NY0LG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NMRA","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":115,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NMRA\",params:#limit:5,,,undefined,":[{"date":"2025-05-12","symbol":"NMRA","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.4,"defaultRemindTime":1747080000000,"name":null,"time":"Post Market","dateTimestamp":1747022400000,"actualEps":null},{"market":"US","date":"2024-11-12","symbol":"NMRA","fiscalQuarterEnding":"2024/09","expectedEps":-0.38,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NMRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NMRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.3333,"hold":0.5556,"sell":0.1111,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.5556,"analysts":9,"updateTime":1743566400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NMRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NMRA","date":"2025-04-29","current":-0.50597,"percent":0.960317,"low":-19.620035,"twenty":-12.279982,"median":-6.898905,"eighty":-1.320222,"high":-0.41859,"avg":-7.884911,"sd":5.021329,"marketCap":123348965},"quantilePoints":[{"date":"2023-09-15","current":-19.620035,"twenty":-19.620035,"median":-19.620035,"eighty":-19.620035,"marketCap":2583134632},{"date":"2023-09-22","current":-12.753675,"twenty":-18.754446,"median":-15.453663,"eighty":-12.753675,"marketCap":1679123396},{"date":"2023-09-28","current":-13.691957,"twenty":-17.415667,"median":-13.628246,"eighty":-12.772209,"marketCap":1802655635},{"date":"2023-10-05","current":-13.813351,"twenty":-16.65135,"median":-13.723658,"eighty":-12.773914,"marketCap":1818638110},{"date":"2023-10-13","current":-11.180579,"twenty":-14.994038,"median":-13.691957,"eighty":-12.763183,"marketCap":1472012710},{"date":"2023-10-20","current":-11.493728,"twenty":-13.94093,"median":-13.080265,"eighty":-11.639864,"marketCap":1513241282},{"date":"2023-10-27","current":-14.254079,"twenty":-14.080107,"median":-13.080265,"eighty":-11.690896,"marketCap":1876663508},{"date":"2023-11-03","current":-10.734234,"twenty":-13.848145,"median":-12.776843,"eighty":-11.493728,"marketCap":1667466680},{"date":"2023-11-10","current":-10.420012,"twenty":-13.826354,"median":-12.7442,"eighty":-11.403032,"marketCap":1618655149},{"date":"2023-11-17","current":-11.79624,"twenty":-13.813351,"median":-12.154821,"eighty":-11.403032,"marketCap":1832439792},{"date":"2023-11-24","current":-11.717599,"twenty":-13.766958,"median":-11.806071,"eighty":-11.438475,"marketCap":1820223526},{"date":"2023-12-01","current":-12.041995,"twenty":-13.704638,"median":-11.815901,"eighty":-11.48267,"marketCap":1870615621},{"date":"2023-12-08","current":-12.26809,"twenty":-13.59002,"median":-11.825731,"eighty":-11.493283,"marketCap":1905737383},{"date":"2023-12-15","current":-14.381583,"twenty":-13.717318,"median":-11.894542,"eighty":-11.493728,"marketCap":2234049513},{"date":"2023-12-22","current":-13.75245,"twenty":-13.821153,"median":-12.041995,"eighty":-11.521564,"marketCap":2136319390},{"date":"2023-12-29","current":-16.848963,"twenty":-14.008036,"median":-12.137729,"eighty":-11.563317,"marketCap":2617334836},{"date":"2024-01-05","current":-16.111698,"twenty":-14.24211,"median":-12.26809,"eighty":-11.573312,"marketCap":2502807349},{"date":"2024-01-12","current":-14.991056,"twenty":-14.660761,"median":-12.728927,"eighty":-11.585874,"marketCap":2328725569},{"date":"2024-01-19","current":-14.411074,"twenty":-14.428768,"median":-12.751722,"eighty":-11.613398,"marketCap":2238630612},{"date":"2024-01-26","current":-14.843603,"twenty":-15.020547,"median":-12.776843,"eighty":-11.648787,"marketCap":2305820071},{"date":"2024-02-02","current":-14.991056,"twenty":-15.264335,"median":-13.370218,"eighty":-11.652719,"marketCap":2328725569},{"date":"2024-02-09","current":-17.1537,"twenty":-15.346909,"median":-13.691957,"eighty":-11.671529,"marketCap":2664672864},{"date":"2024-02-16","current":-18.490607,"twenty":-15.539581,"median":-13.783396,"eighty":-11.691031,"marketCap":2872349373},{"date":"2024-02-23","current":-18.500437,"twenty":-15.932789,"median":-13.819852,"eighty":-11.69454,"marketCap":2873876407},{"date":"2024-03-01","current":-17.330643,"twenty":-16.668088,"median":-13.939224,"eighty":-11.709735,"marketCap":2692159461},{"date":"2024-03-08","current":-12.297819,"twenty":-16.990518,"median":-13.97363,"eighty":-11.717599,"marketCap":2901363004},{"date":"2024-03-15","current":-10.189453,"twenty":-16.81554,"median":-13.826354,"eighty":-11.69454,"marketCap":2403946708},{"date":"2024-03-22","current":-9.414974,"twenty":-16.668088,"median":-13.783396,"eighty":-11.650753,"marketCap":2221227691},{"date":"2024-03-28","current":-8.492333,"twenty":-16.613039,"median":-13.722203,"eighty":-11.579976,"marketCap":2003553733},{"date":"2024-04-05","current":-9.246609,"twenty":-16.364935,"median":-13.534996,"eighty":-11.491504,"marketCap":2181506166},{"date":"2024-04-12","current":-9.435178,"twenty":-16.111698,"median":-12.865966,"eighty":-11.216259,"marketCap":2225994275},{"date":"2024-04-19","current":-7.105005,"twenty":-15.954415,"median":-12.753675,"eighty":-10.606446,"marketCap":1676248365},{"date":"2024-04-26","current":-6.123304,"twenty":-15.846283,"median":-12.728927,"eighty":-10.162515,"marketCap":1444640411},{"date":"2024-05-03","current":-6.231441,"twenty":-15.669339,"median":-12.297819,"eighty":-9.792112,"marketCap":1470152824},{"date":"2024-05-10","current":-6.135514,"twenty":-15.610358,"median":-12.155389,"eighty":-9.435178,"marketCap":1558549450},{"date":"2024-05-17","current":-6.047595,"twenty":-15.433415,"median":-12.120637,"eighty":-9.273547,"marketCap":1536216091},{"date":"2024-05-24","current":-5.846636,"twenty":-15.423584,"median":-11.91675,"eighty":-8.957021,"marketCap":1485168412},{"date":"2024-05-31","current":-6.085275,"twenty":-15.399992,"median":-11.884712,"eighty":-8.469435,"marketCap":1545787530},{"date":"2024-06-07","current":-6.235993,"twenty":-15.362637,"median":-11.806071,"eighty":-7.09423,"marketCap":1584073290},{"date":"2024-06-14","current":-6.248553,"twenty":-15.342977,"median":-11.75692,"eighty":-6.904314,"marketCap":1587263770},{"date":"2024-06-21","current":-5.557759,"twenty":-15.335113,"median":-11.717599,"eighty":-6.419582,"marketCap":1411787373},{"date":"2024-06-28","current":-5.777557,"twenty":-15.335113,"median":-11.707769,"eighty":-6.279953,"marketCap":1467620772},{"date":"2024-07-05","current":-6.129234,"twenty":-15.228947,"median":-11.690896,"eighty":-6.264891,"marketCap":1556954210},{"date":"2024-07-12","current":-7.253346,"twenty":-15.12278,"median":-11.653703,"eighty":-6.277441,"marketCap":1842502165},{"date":"2024-07-15","current":-6.939348,"twenty":-15.110984,"median":-11.648787,"eighty":-6.278697,"marketCap":1762740166},{"date":"2024-08-02","current":-7.931581,"twenty":-15.099188,"median":-11.648787,"eighty":-6.279953,"marketCap":2014788082},{"date":"2024-08-09","current":-6.56038,"twenty":-15.040207,"median":-11.579976,"eighty":-6.279953,"marketCap":1798711865},{"date":"2024-08-16","current":-6.881395,"twenty":-14.991056,"median":-11.493728,"eighty":-6.279953,"marketCap":1886727125},{"date":"2024-08-23","current":-6.712133,"twenty":-14.991056,"median":-11.447336,"eighty":-6.393648,"marketCap":1840319079},{"date":"2024-08-30","current":-6.54287,"twenty":-14.922244,"median":-11.299816,"eighty":-6.436952,"marketCap":1793911032},{"date":"2024-09-06","current":-6.297731,"twenty":-14.859331,"median":-10.957407,"eighty":-6.374465,"marketCap":1726699379},{"date":"2024-09-13","current":-6.904742,"twenty":-14.68632,"median":-10.606446,"eighty":-6.374465,"marketCap":1893128235},{"date":"2024-09-20","current":-7.430039,"twenty":-14.481851,"median":-10.304733,"eighty":-6.410301,"marketCap":2037153206},{"date":"2024-09-27","current":-7.634321,"twenty":-14.416972,"median":-9.973946,"eighty":-6.432454,"marketCap":2093162917},{"date":"2024-10-04","current":-7.905725,"twenty":-14.387481,"median":-9.835887,"eighty":-6.454177,"marketCap":2167575819},{"date":"2024-10-11","current":-8.988421,"twenty":-14.365855,"median":-9.536197,"eighty":-6.471402,"marketCap":2464427288},{"date":"2024-10-18","current":-9.898936,"twenty":-14.275648,"median":-9.492422,"eighty":-6.494727,"marketCap":2714070572},{"date":"2024-10-25","current":-7.587628,"twenty":-14.23812,"median":-9.435178,"eighty":-6.5109,"marketCap":2080360698},{"date":"2024-10-31","current":-7.126534,"twenty":-14.186945,"median":-9.414974,"eighty":-6.517189,"marketCap":1953938778},{"date":"2024-11-08","current":-7.599301,"twenty":-14.11026,"median":-9.329429,"eighty":-6.519524,"marketCap":2083561252},{"date":"2024-11-15","current":-6.430581,"twenty":-14.036864,"median":-9.246609,"eighty":-6.508113,"marketCap":1888648838},{"date":"2024-11-22","current":-5.330396,"twenty":-14.008036,"median":-9.078889,"eighty":-6.434404,"marketCap":1565526710},{"date":"2024-11-29","current":-5.467919,"twenty":-13.980511,"median":-8.972721,"eighty":-6.336098,"marketCap":1605916976},{"date":"2024-12-06","current":-5.313893,"twenty":-13.902792,"median":-8.614876,"eighty":-6.276185,"marketCap":1560679878},{"date":"2024-12-13","current":-5.819979,"twenty":-13.839429,"median":-8.495238,"eighty":-6.248553,"marketCap":1709316057},{"date":"2024-12-20","current":-5.775971,"twenty":-13.821153,"median":-8.377845,"eighty":-6.222869,"marketCap":1696391172},{"date":"2024-12-27","current":-6.238049,"twenty":-13.812967,"median":-8.200475,"eighty":-6.175381,"marketCap":1832102465},{"date":"2025-01-03","current":-1.083682,"twenty":-13.811432,"median":-8.147945,"eighty":-6.157876,"marketCap":318275296},{"date":"2025-01-10","current":-1.303719,"twenty":-13.766574,"median":-7.931581,"eighty":-6.140538,"marketCap":382899721},{"date":"2025-01-17","current":-1.193701,"twenty":-13.753032,"median":-7.891133,"eighty":-6.119668,"marketCap":350587508},{"date":"2025-01-24","current":-1.1882,"twenty":-13.716154,"median":-7.812392,"eighty":-6.085275,"marketCap":348971898},{"date":"2025-01-31","current":-1.056178,"twenty":-13.615504,"median":-7.634321,"eighty":-6.067691,"marketCap":310197242},{"date":"2025-02-07","current":-1.07268,"twenty":-13.546812,"median":-7.564281,"eighty":-5.978405,"marketCap":315044074},{"date":"2025-02-14","current":-0.929656,"twenty":-13.337262,"median":-7.53602,"eighty":-5.966304,"marketCap":273038198},{"date":"2025-02-21","current":-0.940658,"twenty":-13.1053,"median":-7.470895,"eighty":-5.920328,"marketCap":276269419},{"date":"2025-02-28","current":-0.852643,"twenty":-12.883791,"median":-7.424202,"eighty":-5.847483,"marketCap":250419649},{"date":"2025-03-07","current":-1.009931,"twenty":-12.773914,"median":-7.253346,"eighty":-5.800175,"marketCap":246207962},{"date":"2025-03-14","current":-0.930199,"twenty":-12.763183,"median":-7.144044,"eighty":-5.763741,"marketCap":226770492},{"date":"2025-03-21","current":-0.770737,"twenty":-12.752113,"median":-7.105005,"eighty":-5.687956,"marketCap":187895550},{"date":"2025-03-28","current":-0.730871,"twenty":-12.743752,"median":-7.036301,"eighty":-5.574632,"marketCap":178176815},{"date":"2025-04-04","current":-0.564099,"twenty":-12.730087,"median":-6.998128,"eighty":-5.417311,"marketCap":137520105},{"date":"2025-04-11","current":-0.476129,"twenty":-12.580434,"median":-6.945391,"eighty":-5.374404,"marketCap":116074096},{"date":"2025-04-17","current":-0.41859,"twenty":-12.352677,"median":-6.926527,"eighty":-5.321594,"marketCap":102046721},{"date":"2025-04-25","current":-0.497989,"twenty":-12.291873,"median":-6.904742,"eighty":-1.375231,"marketCap":121403202},{"date":"2025-04-29","current":-0.50597,"twenty":-12.279982,"median":-6.898905,"eighty":-1.320222,"marketCap":123348965}],"updateTime":1746086020632}}}